Dividend Alert!

Here's the list:

Moelis & Company
Ticker: MC
Recent Price: $64.11
Average Analyst Price Target: $65.67 (2.43%)
Market Cap: $4.51B
Last Dividend Amount: $0.60
Expected Ex-Dividend Date: Aug 05 2024
Expected Payment Date: Sep 26 2024
Expected Dividend & Yield: 3.74%

Summary: Moelis & Company is a global investment bank, providing strategic and financial advisory services to corporations, governments and financial sponsors across all major industries. The company's advisory services include M&As, capital markets transactions, recapitalizations and restructurings, and other corporate finance matters like public/private debt and equity transactions. The company serves clients with the help of advisory professionals who are based across the Americas, Europe, the Middle East, Asia and Australia.

Here are 3^rd party ratings for MC:

• TipRanks.com: Hold
• Barchart.com: Strong buy
• Zacks.com: Hold, Bottom 30% (176 out of 250)

Click for chart >> 

Blue Owl Capital Inc.
Ticker: OWL
Recent Price: $17.19
Average Analyst Price Target: $20.00 (16.35%)
Market Cap: $25.16B
Last Dividend Amount: $0.00
Expected Ex-Dividend Date: Aug 21 2024
Expected Payment Date: Aug 30 2024
Expected Dividend & Yield: 4.19%

Summary: Blue Owl Capital is an alternative asset manager which provides investors access to direct lending and GP capital solutions strategies through a variety of vehicles. Blue Owl Capital, formerly known as Altimar Acquisition Corporation, is based in NEW YORK.

Here are 3^rd party ratings for OWL:

• TipRanks.com: Buy
• Barchart.com: sell
• Zacks.com: Hold, Bottom 42% (146 out of 250)

Click for chart >> 

The Clorox Company
Ticker: CLX
Recent Price: $164.97
Average Analyst Price Target: $154.75 (-6.20%)
Market Cap: $20.43B
Last Dividend Amount: $1.22
Expected Ex-Dividend Date: Aug 14 2024
Expected Payment Date: Aug 30 2024
Expected Dividend & Yield: 2.96%

Summary: The Clorox Company is engaged in the production, marketing and sale of consumer products in the U.S. and international markets. The company sells its products primarily through mass merchandisers, grocery stores and other retail outlets. Clorox markets some of the most trusted and recognized brands, including its namesake bleach and cleaning products, Green Works natural cleaners and laundry products, Poett and Mistolin cleaning products, Armor All and STP auto-care products, Fresh Step and Scoop Away cat litter, Kingsford charcoal, Hidden Valley and K C Masterpiece dressings and sauces, Brita water-filtration systems, Glad bags, wraps and containers, and Burt's Bees natural personal care products.

Here are 3^rd party ratings for CLX:

• TipRanks.com: Hold
• Barchart.com: Strong buy
• Zacks.com: Hold, Top 16% (41 out of 250)

Click for chart >> 

Cisco Systems, Inc.
Ticker: CSCO
Recent Price: $49.61
Average Analyst Price Target: $57.25 (15.40%)
Market Cap: $197.98B
Last Dividend Amount: $0.40
Expected Ex-Dividend Date: Oct 02 2024
Expected Payment Date: Oct 23 2024
Expected Dividend & Yield: 3.23%

Summary: Cisco Systems Inc. is an IP-based networking company offering products and services to service providers, companies, commercial users and individuals. Cisco is rapidly expanding its presence in network security domain. Security includes products and services preventing unauthorized access to system resources and protecting from worms, spam, viruses and other malware. The Data Center product category includes Cisco Unified Computing System (UCS) and Server Access Virtualization. It also comprises of The Other products segment and Related Services.The company offers identity and access, advanced threat, and unified threat management solutions. The company has introduced Secure Remote Worker, which leverages Zero Trust Architecture, combined with robust endpoint security portfolio of AnyConnect, Umbrella, Duo and AMP for Endpoints.Cisco provides Next-Generation Network (NGN) Routers, that transport data, voice and video information from one IP network to another.

Here are 3^rd party ratings for CSCO:

• TipRanks.com: Buy
• Barchart.com: buy
• Zacks.com: Hold, Top 38% (95 out of 250)

Click for chart >> 

Chevron Corporation
Ticker: CVX
Recent Price: $139.23
Average Analyst Price Target: $176.00 (26.41%)
Market Cap: $254.64B
Last Dividend Amount: $1.63
Expected Ex-Dividend Date: Aug 19 2024
Expected Payment Date: Sep 10 2024
Expected Dividend & Yield: 4.68%

Summary: Chevron is one of the largest publicly traded oil and gas companies in the world with operations that span almost every corner of the globe. The only energy component of the Dow Jones Industrial Average, Chevron is fully integrated, meaning it participates in every aspect related to energy from oil production, to refining and marketing. Chevron remains well positioned to navigate the volatility in oil and gas prices.Being an integrated firm engaged in all aspects of the oil and gas business. Chevron divides its operations into two main segments: Upstream and Downstream. Chevron's other activities include transportation and chemicals. Chevron's current oil and gas development project pipeline is among the best in the industry.

Here are 3^rd party ratings for CVX:

• TipRanks.com: Buy
• Barchart.com: Strong sell
• Zacks.com: Hold, Bottom 12% (221 out of 250)

Click for chart >> 

Gilead Sciences, Inc.
Ticker: GILD
Recent Price: $83.16
Average Analyst Price Target: $84.20 (1.25%)
Market Cap: $103.53B
Last Dividend Amount: $0.77
Expected Ex-Dividend Date: Sep 13 2024
Expected Payment Date: Sep 27 2024
Expected Dividend & Yield: 3.70%

Summary: Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.

Here are 3^rd party ratings for GILD:

• TipRanks.com: Hold
• Barchart.com: Strong buy
• Zacks.com: Hold, Top 32% (80 out of 250)

Click for chart >> 

And there you have it.

We hope this report provides you with valuable insights to enhance your dividend investment strategy.

For any specific inquiries regarding dividends, we recommend consulting with your financial advisor or visiting Investor.gov for more comprehensive information.

Best regards,

The Editor